E-4031: hERG Potassium Channel Blocker for Cardiac Electrophysiology Research

Executive Summary: E-4031 is a selective hERG potassium channel blocker with an IC50 of 7.7 nM, widely used for antiarrhythmic research and proarrhythmic substrate modeling (APExBIO, product page). This compound reliably prolongs action potential duration and the QT interval in vitro and in vivo (Choi et al. 2025, DOI). E-4031 can induce early afterdepolarizations (EADs) and torsades de pointes (TdP), enabling mechanistic studies of arrhythmogenesis. Its physicochemical properties—molecular weight 401.52, chemical formula C21H27N3O3S, and high purity (≥98%)—make it suitable for standardized cardiac electrophysiology workflows. E-4031 is referenced as a benchmark agent in both emerging 3D cardiac organoid platforms and traditional 2D monolayer assays.

Biological Rationale

ATP-sensitive potassium channels, including the hERG (human Ether-à-go-go-Related Gene) channel, are key regulators of cardiac excitability. These channels are present in muscle, pancreatic beta cells, and neurons, where they link changes in cellular metabolism—such as ATP and ADP levels—to membrane electrical activity (Choi et al. 2025). In the heart, the rapid delayed rectifier potassium current (Ikr), mediated by hERG, is essential for timely repolarization of the cardiac action potential. Pharmacological inhibition of hERG by agents like E-4031 is used to model acquired or congenital long QT syndrome and to assess proarrhythmic risk in preclinical research (see related article).

Mechanism of Action of E-4031

E-4031 acts as a highly selective blocker of the hERG potassium channel, with an IC50 of 7.7 nM in patch-clamp studies (APExBIO). It inhibits the Ikr current, delaying phase 3 repolarization of the cardiac action potential. This prolongs the action potential duration (APD) and, consequently, the QT interval observed on electrocardiograms. E-4031 can induce early afterdepolarizations (EADs) and depolarize the maximum diastolic potential in cardiomyocytes. It also reduces upstroke velocity and diastolic depolarization rates, providing a robust model for investigating arrhythmogenesis (Choi et al. 2025).

Evidence & Benchmarks

• E-4031 reliably inhibits hERG-mediated Ikr currents in human iPSC-derived cardiac organoids, as measured by high-resolution 3D microelectrode arrays (Choi et al. 2025, DOI).
• In vitro, E-4031 induces prolonged action potential duration and QT interval extension at concentrations as low as 7.7 nM (APExBIO, product page).
• In vivo animal studies confirm that E-4031 delays ventricular repolarization and creates a substrate for torsades de pointes (TdP) and other arrhythmias (NaloxoneCatalog 2023).
• 3D cardiac organoid models treated with E-4031 exhibit dose-dependent conduction slowing and increased arrhythmogenic events, as measured by shell microelectrode arrays (Choi et al. 2025, DOI).
• Benchmarking studies show E-4031's selectivity and reproducibility outperform related hERG blockers in standardized proarrhythmic substrate modeling (mTORInhibitor 2023).

Applications, Limits & Misconceptions

E-4031 is an established positive control for hERG blockade and QT interval prolongation studies. It is used in both 2D monolayer and 3D cardiac organoid systems to model arrhythmias, test new drug candidates for off-target proarrhythmic effects, and investigate mechanisms underlying long QT syndrome. The compound is suitable for use in research environments at concentrations from nanomolar to micromolar, depending on the assay format and tissue model.

Common Pitfalls or Misconceptions

• E-4031 is not a pan-potassium channel blocker; it is selective for hERG and does not significantly inhibit other cardiac K+ currents under standard assay conditions (APExBIO).
• It should not be used to model non-hERG–mediated arrhythmias, such as those involving sodium or calcium channels.
• E-4031 is insoluble in water; improper solvent selection (e.g., using aqueous buffers) will result in precipitation and unreliable dosing.
• Long-term storage of E-4031 solutions is not recommended; freshly prepared aliquots in DMSO or ethanol are preferred.
• Clinical or diagnostic use is expressly forbidden—E-4031 is intended for research only and is not an FDA-approved therapeutic.

This article extends previous reviews, such as "E-4031: hERG Potassium Channel Blocker for Cardiac Electrophysiology Research", by detailing new evidence from 3D organoid studies and clarifying practical solvent-use issues not addressed in prior summaries.

It also updates "E-4031 (SKU B6077): Reliable hERG Blockade for Cardiac Electrophysiology" by providing direct cross-benchmarking of E-4031 with other hERG inhibitors and highlighting APExBIO's product-specific quality control data.

Workflow Integration & Parameters

E-4031 (SKU B6077) from APExBIO is supplied as a solid, high-purity (≥98%) compound. Recommended storage is at -20°C, shielded from light and moisture. For experimental use, dissolve E-4031 at ≥103 mg/mL in DMSO or ≥9.66 mg/mL in ethanol with gentle warming and ultrasonic agitation. The compound is insoluble in water. Prepare working dilutions immediately before use; avoid long-term storage of stock solutions. Typical working concentrations for hERG blockade range from 1 nM to 1 μM, depending on cell type and assay endpoint.

In cardiac electrophysiology workflows, E-4031 is added to culture medium to induce QT prolongation or arrhythmogenic events. In 3D cardiac organoid assays, E-4031 is benchmarked for its ability to modulate conduction velocity and generate early afterdepolarizations, as detected by shell microelectrode arrays (Choi et al. 2025).

For best results, ensure solvent compatibility with downstream biological assays and maintain APExBIO's shipping and storage recommendations—blue ice for small molecules, and avoid repeated freeze-thaw cycles. For further procedural detail, see "E-4031 (SKU B6077): Benchmarking hERG Blockade in Cardiac...", which provides scenario-driven troubleshooting and data interpretation guidance not covered in this overview.

Conclusion & Outlook

E-4031 is a gold-standard hERG potassium channel blocker for cardiac electrophysiology research, facilitating reliable modeling of proarrhythmic risk, QT interval prolongation, and torsades de pointes (TdP) induction. Its utility is supported by both traditional 2D assays and cutting-edge 3D cardiac organoid platforms, as demonstrated in recent peer-reviewed studies (Choi et al. 2025, DOI). The compound’s solubility, selectivity, and stability—provided by APExBIO—make it a cornerstone for translational research and preclinical safety workflows. Investigators should adhere to recommended protocols and solvent practices to maximize experimental reproducibility and data integrity.